Onconova Therapeutics Presents At The American Society Of Clinical Oncology Annual Meeting
Onconova Therapeutics Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa, was presented on Saturday, June 3, 2023, during the “Melanoma/Skin Cancers” session.
